Clinical trials: Rosacea
Rosacea
Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
A long-term, open-label, non-comparative safety and efficacy study of CD07805/47 gel 0.5% once daily in subjects with moderate to severe facial erythema associated with rosacea.
- Trial name
- NCT01318733
- Testing
- CD07805/47 gel 0.5%
- Where
- 27 sites in United States
- Volunteers
- 449 people
- Sponsor
- Galderma R&D
Rosacea
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and…
- Trial name
- NCT01355458
- Testing
- CD07805/47 gel
- Where
- 15 sites in United States, Canada
- Volunteers
- 260 people
- Sponsor
- Galderma R&D
Rosacea
Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea
This is a Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than…
- Trial name
- NCT01355471
- Testing
- CD07805/47 Gel
- Where
- 15 sites in United States, Canada
- Volunteers
- 293 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea (PPR)
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01493687
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 683 people
- Sponsor
- Galderma R&D
Papulopustular Rosacea
Phase 3 Papulopustular Rosacea Study
The purpose of this study is to demonstrate that CD5024 1% cream is more effective than its vehicle when applied once daily, at bed time, during a 12 week period in subjects with Papulopustular Rosacea (PPR) and continues to be…
- Trial name
- NCT01494467
- Testing
- CD5024, Azelaic acid 15% Gel
- Where
- 50 sites in United States, Canada
- Volunteers
- 688 people
- Sponsor
- Galderma R&D
Rosacea
MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.
The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to…
- Trial name
- MOSAIC (NCT02616250)
- Testing
- Brimonidine 0.33% gel (Br), Ivermectin 1% cream (IVM)
- Where
- 13 sites in United States, Canada
- Volunteers
- 190 people
- Sponsor
- Galderma R&D
Facial Papulopustular Rosacea
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT03142451
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 54 sites in United States
- Volunteers
- 751 people
- Sponsor
- Vyne Therapeutics Inc.
Acne Rosacea
A Pilot Study on the Use of Seysara for Rosacea
This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult…
- Trial name
- NCT04555525
- Testing
- sarecycline, Centrum Adult Multivitamin
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Derm Research, PLLC
Facial Papulopustular Rosacea
A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
- Trial name
- NCT04608500
- Testing
- FMX103 minocycline foam 1.5%, Vehicle foam
- Where
- 46 sites in United States
- Volunteers
- 771 people
- Sponsor
- Vyne Therapeutics Inc.
Rosacea
A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
This is a double-blinded, randomized placebo controlled pilot study comparing the efficacy and safety of incobotulinumtoxinA versus saline injections to the cheek region in patients with rosacea.
- Trial name
- NCT01614743
- Testing
- IncobotulinumtoxinA, Bacteriostatic saline
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- DeNova Research
Rosacea
A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea
The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.
- Trial name
- NCT02120924
- Testing
- Azelaic acid, Vehicle, Finacea
- Where
- 30 sites in United States
- Volunteers
- 1,009 people
- Sponsor
- Actavis Inc.
Moderate to Severe Papulopustular Rosacea
Clinical Endpoint Study of Ivermectin 1% Cream
A randomized, double-blind, placebo-controlled, parallel-design, multiple-site clinical study to evaluate the therapeutic equivalence and safety of ivermectin cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (ivermectin)…
- Trial name
- NCT02840461
- Testing
- Ivermectin Cream, 1%
- Where
- United States
- Volunteers
- 630 people
- Sponsor
- Actavis Inc.
Papulopustular Rosacea
Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
This exploratory study is being performed to determine whether a new form formulation of azelaic acid 15% is effective in the treatment of papulopustular rosecea.
- Trial name
- NCT00617903
- Testing
- Azelaic acid, Vehicle foam
- Where
- 7 sites in United States
- Volunteers
- 83 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
Subjects with moderate papulopustular rosacea will be treated either with azelaic acid 15% gel topically plus an anti-inflammatory dose of doxycyline (40mg) daily or with metronidazole 1% gel topically once daily plus an…
- Trial name
- NCT00855595
- Testing
- Azelaic acid (Finacea, BAY39-6251), Metronidazole (Metrogel), Doxycycline (Oracea)
- Where
- 17 sites in United States
- Volunteers
- 207 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea
This study will investigate the safety and efficacy of a new formulation of an existing medication for the treatment of papulopustular rosacea. The study will test the active ingredient plus foam against foam alone.
- Trial name
- NCT01025635
- Testing
- Azelaic acid foam 15%, Vehicle foam
- Where
- 20 sites in United States
- Volunteers
- 401 people
- Sponsor
- LEO Pharma
Papulopustular Rosacea
Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea
This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer…
- Trial name
- NCT03079531
- Testing
- Secukinumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Anne Chang
Rosacea
Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea
A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product…
- Trial name
- NCT02289352
- Testing
- Brimonidine
- Where
- 16 sites in United States
- Volunteers
- 462 people
- Sponsor
- Actavis Inc.
Ocular Rosacea, Dry Eye
Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
Dry eye disease (DED) is a common condition that causes ocular discomfort and reduces visual acuity. The two categories of DED are evaporative dry eye and aqueous deficient dry eye.
- Trial name
- NCT03194698
- Testing
- Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Rosacea, Erythema
Safety and Tolerability of AGN-199201 in Patients With Erythema Associated With Rosacea
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.
- Trial name
- NCT01579084
- Testing
- AGN-199201 Formulation A, AGN-199201 Formulation B, AGN-199201 Formulation C
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Allergan
Erythema, Rosacea
Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale
This is a study to evaluate inter- and intra-rater reliability of the Clinician Erythema Assessment Scale. There is no treatment (intervention) associated with this study.
- Trial name
- NCT01636765
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Allergan